Baseline characteristics and response
| Characteristic . | Total patients, N (%) . | Patients treated with frontline therapy, n (%) . |
|---|---|---|
| Total patients | 77 (100) | 72 (100) |
| Age, y | ||
| <60 | 43 (55.8) | 42 (58.3) |
| ≥60 | 34 (44.2) | 30 (41.7) |
| Median (25th percentile-75th percentile) | 56 (46-67) | 55.5 (46-66) |
| Sex | ||
| Female | 30 (39) | 27 (37.5) |
| Male | 47 (61) | 45 (62.5) |
| Race, n (%) | 73 (100) | 68 (100) |
| White | 62 (84.9) | 57 (83.8) |
| Black | 7 (9.6) | 7 (10.3) |
| Asian | 4 (5.5) | 4 (5.9) |
| Ethnicity | ||
| Hispanic | 17 (22.1) | 16 (22.2) |
| Non-Hispanic | 60 (77.9) | 56 (77.8) |
| ECOG performance status, n (%) | 73 (100) | 69 (100) |
| 0-1 | 68 (93.2) | 65 (94.3) |
| 2-3 | 5 (6.8) | 4 (5.7) |
| Bulky disease, n (%) | 75 (100) | 70 (100) |
| No | 57 (76) | 52 (74.3) |
| Yes | 18 (24) | 18 (25.7) |
| FLIPI score, n (%) | 76 (100) | 71 (100) |
| 0-1 | 10 (13.1) | 8 (11.3) |
| 2 | 19 (25) | 17 (23.9) |
| 3-5 | 47 (61.9) | 46 (64.8) |
| B symptoms, n (%) | 76 (100) | 71 (100) |
| No | 44 (57.9) | 41 (57.7) |
| Yes | 32 (42.1) | 30 (42.3) |
| Bone marrow involvement, n (%) | 69 (100) | 66 (100) |
| No | 2 (2.9)∗ | 2 (3) |
| Yes | 67 (97.1) | 64 (97) |
| Elevated LDH, n (%) | 68 (100) | 65 (100) |
| No | 38 (55.9) | 36 (55.4) |
| Yes | 30 (44.1) | 29 (44.6) |
| WBC at diagnosis (×109/L), n (%) | 73 (100) | 69 (100) |
| Median (25th percentile-75th percentile) | 14.2 (8-25.1) | 16.3 (8-25.8) |
| ALC at diagnosis (×109/L), n (%) | 72 (100) | 68 (100) |
| Median (25th percentile-75th percentile) | 7.38 (1.75-16.51) | 8.09 (1.94-18.51) |
| Primary symptom at diagnosis, n (%) | 76 (100) | 71 (100) |
| B symptoms | 21 (27.6) | 21 (29.6) |
| Asymptomatic leukocytosis | 16 (21.1) | 12 (16.9) |
| Asymptomatic lymphadenopathy | 28 (36.8) | 27 (38) |
| Organ compromise | 4 (5.3) | 4 (5.6) |
| Other | 7 (9.2) | 6 (8.5) |
| Circulating lymphoma cells (×109/L) | ||
| <5 | 40 (52) | 36 (50) |
| ≥5 | 37 (48) | 36 (50) |
| Median (25th percentile-75th percentile) | 4.8 (0.3-13.4) | 5.07 (0.48-14.2) |
| Ki67, n (%) | 55 (100) | 51 (100) |
| 0-25 | 31 (56.4) | 29 (56.9) |
| 26-50 | 15 (27.3) | 15 (29.4) |
| 50-85 | 9 (16.4) | 7 (13.7) |
| Median (25th percentile-75th percentile) | 20 (10-40) | 20 (10-40) |
| CD10 positive in lymph node, n (%) | 75 (100) | 70 (100) |
| BCL-2 FISH positive, n (%) | 42 (100) | 41 (100) |
| No | 1 (2.4) | 0 (0) |
| Yes | 41 (97.6) | 41 (100) |
| MYC FISH positive, n (%) | 30 (100) | 30 (100) |
| No | 27 (90) | 27 (90) |
| Yes | 3 (10) | 3 (10) |
| Frontline therapy, n (%) | ||
| Anti-CD20 | 10 (13.0) | 10 (13.9) |
| Anti-CD20 + bendamustine | 36 (46.8) | 36 (50.0) |
| Anti-CD20 + CHOP | 22 (28.6) | 22 (30.6) |
| Surveillance | 5 (6.5) | N/A |
| Other | 4 (5.2) | 4 (5.6) |
| Best response from frontline therapy, n (%) | 73 (100) | 70 (100) |
| CR | 47 (64.4) | 47 (67.1) |
| PR | 16 (21.9) | 16 (22.9) |
| SD | 5 (6.8) | 2 (2.9) |
| PD | 5 (6.8) | 5 (7.1) |
| Death | ||
| No (alive) | 56 (72.7) | 52 (72.2) |
| Yes (dead) | 21 (27.3) | 20 (27.8) |
| POD24† , n (%) | 62 (100) | 50 (100)‡ |
| No | 37 (59.7) | 29 (58.0) |
| Yes | 25 (40.3) | 21 (42.0) |
| Characteristic . | Total patients, N (%) . | Patients treated with frontline therapy, n (%) . |
|---|---|---|
| Total patients | 77 (100) | 72 (100) |
| Age, y | ||
| <60 | 43 (55.8) | 42 (58.3) |
| ≥60 | 34 (44.2) | 30 (41.7) |
| Median (25th percentile-75th percentile) | 56 (46-67) | 55.5 (46-66) |
| Sex | ||
| Female | 30 (39) | 27 (37.5) |
| Male | 47 (61) | 45 (62.5) |
| Race, n (%) | 73 (100) | 68 (100) |
| White | 62 (84.9) | 57 (83.8) |
| Black | 7 (9.6) | 7 (10.3) |
| Asian | 4 (5.5) | 4 (5.9) |
| Ethnicity | ||
| Hispanic | 17 (22.1) | 16 (22.2) |
| Non-Hispanic | 60 (77.9) | 56 (77.8) |
| ECOG performance status, n (%) | 73 (100) | 69 (100) |
| 0-1 | 68 (93.2) | 65 (94.3) |
| 2-3 | 5 (6.8) | 4 (5.7) |
| Bulky disease, n (%) | 75 (100) | 70 (100) |
| No | 57 (76) | 52 (74.3) |
| Yes | 18 (24) | 18 (25.7) |
| FLIPI score, n (%) | 76 (100) | 71 (100) |
| 0-1 | 10 (13.1) | 8 (11.3) |
| 2 | 19 (25) | 17 (23.9) |
| 3-5 | 47 (61.9) | 46 (64.8) |
| B symptoms, n (%) | 76 (100) | 71 (100) |
| No | 44 (57.9) | 41 (57.7) |
| Yes | 32 (42.1) | 30 (42.3) |
| Bone marrow involvement, n (%) | 69 (100) | 66 (100) |
| No | 2 (2.9)∗ | 2 (3) |
| Yes | 67 (97.1) | 64 (97) |
| Elevated LDH, n (%) | 68 (100) | 65 (100) |
| No | 38 (55.9) | 36 (55.4) |
| Yes | 30 (44.1) | 29 (44.6) |
| WBC at diagnosis (×109/L), n (%) | 73 (100) | 69 (100) |
| Median (25th percentile-75th percentile) | 14.2 (8-25.1) | 16.3 (8-25.8) |
| ALC at diagnosis (×109/L), n (%) | 72 (100) | 68 (100) |
| Median (25th percentile-75th percentile) | 7.38 (1.75-16.51) | 8.09 (1.94-18.51) |
| Primary symptom at diagnosis, n (%) | 76 (100) | 71 (100) |
| B symptoms | 21 (27.6) | 21 (29.6) |
| Asymptomatic leukocytosis | 16 (21.1) | 12 (16.9) |
| Asymptomatic lymphadenopathy | 28 (36.8) | 27 (38) |
| Organ compromise | 4 (5.3) | 4 (5.6) |
| Other | 7 (9.2) | 6 (8.5) |
| Circulating lymphoma cells (×109/L) | ||
| <5 | 40 (52) | 36 (50) |
| ≥5 | 37 (48) | 36 (50) |
| Median (25th percentile-75th percentile) | 4.8 (0.3-13.4) | 5.07 (0.48-14.2) |
| Ki67, n (%) | 55 (100) | 51 (100) |
| 0-25 | 31 (56.4) | 29 (56.9) |
| 26-50 | 15 (27.3) | 15 (29.4) |
| 50-85 | 9 (16.4) | 7 (13.7) |
| Median (25th percentile-75th percentile) | 20 (10-40) | 20 (10-40) |
| CD10 positive in lymph node, n (%) | 75 (100) | 70 (100) |
| BCL-2 FISH positive, n (%) | 42 (100) | 41 (100) |
| No | 1 (2.4) | 0 (0) |
| Yes | 41 (97.6) | 41 (100) |
| MYC FISH positive, n (%) | 30 (100) | 30 (100) |
| No | 27 (90) | 27 (90) |
| Yes | 3 (10) | 3 (10) |
| Frontline therapy, n (%) | ||
| Anti-CD20 | 10 (13.0) | 10 (13.9) |
| Anti-CD20 + bendamustine | 36 (46.8) | 36 (50.0) |
| Anti-CD20 + CHOP | 22 (28.6) | 22 (30.6) |
| Surveillance | 5 (6.5) | N/A |
| Other | 4 (5.2) | 4 (5.6) |
| Best response from frontline therapy, n (%) | 73 (100) | 70 (100) |
| CR | 47 (64.4) | 47 (67.1) |
| PR | 16 (21.9) | 16 (22.9) |
| SD | 5 (6.8) | 2 (2.9) |
| PD | 5 (6.8) | 5 (7.1) |
| Death | ||
| No (alive) | 56 (72.7) | 52 (72.2) |
| Yes (dead) | 21 (27.3) | 20 (27.8) |
| POD24† , n (%) | 62 (100) | 50 (100)‡ |
| No | 37 (59.7) | 29 (58.0) |
| Yes | 25 (40.3) | 21 (42.0) |
ALC, absolute lymphocyte count; CHOP, cyclophosphamide, adriamycin, vincristine and prednisone; FISH, fluorescence in situ hybridization; LDH, lactate dehydrogenase; PB, peripheral blood; PD, progressive disease; SD, stable disease; WBC, white blood cell.
These 2 patients had circulating lymphoma cells of 0.1 × 109/L and 1.4 × 109/L. Negative bone marrow could be related to sampling error.
POD24: progression of disease at 24 months, which is not available for patients with follow-up <24 months.
Excluding patients who received single-agent anti-CD20 at first line.